Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liposomal Bupivacaine in Cesarean Delivery
NCT04232306Phase 4Withdrawn
- Sponsor
- Wake Forest University Health Sciences
- Start
- Mar 2024
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of liposomal bupivacaine in postoperative pain (2 arms), sponsored by Wake Forest University Health Sciences. Primary endpoint: Amount of total opioid MME consumed at 72 hours. Planned start Mar 2024; status: withdrawn.
02
Drugs
liposomal bupivacaine
03
Conditions
postoperative pain
Beyond the preview
Go deeper on NCT04232306.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04232306.